Home/Revolo Biotherapeutics/Jorge De Alba, Ph.D.

JD

Jorge De Alba, Ph.D.

Vice President, Discovery and Translational Science

Revolo Biotherapeutics

Therapeutic Areas

Autoimmune Diseases Allergic Diseases

Revolo Biotherapeutics Pipeline

Drug	Indication	Phase
'1104	Eosinophilic Esophagitis (EoE)	Phase 2
'1805	Rheumatoid Arthritis	Phase 2 (Planned)

Leadership Team at Revolo Biotherapeutics

Kari Brown, M.D.

Chief Medical Officer

David Southwell

Paul Eggleton, Ph.D.

Vice President, Immunology

Maria Pittaras, PMP

Vice President, Portfolio and Program Management

Vice President, Technical Operations, CMC

View full Revolo Biotherapeutics profile